2016
Preclinical Pharmacology of CW002
Sunaga H, Savarese JJ, McGilvra JD, Heerdt PM, Belmont MR, Van Ornum SG, Murrell MT, Malhotra JK, Savard PM, Jeannotte E, Petty BJ, Allen E, Carnathan GW. Preclinical Pharmacology of CW002. Anesthesiology 2016, 125: 732-743. PMID: 27466033, DOI: 10.1097/aln.0000000000001254.Peer-Reviewed Original ResearchMean arterial pressureNeuromuscular blockadeArterial pressureNondepolarizing neuromuscular blocking agentDose ratioSympathetic autonomic responsesNeuromuscular blocking agentsNeuromuscular blocking propertiesRecovery intervalIncrease of HRSympathetic inhibitionBolus dosesCirculatory effectsPreclinical pharmacologyTwitch inhibitionBlocking agentStudy of safetyInstitutional Animal CareAnesthetized monkeysHeart rateSpontaneous recoveryED95CW002Autonomic responsesRapid reversal
2015
Novel neuromuscular blocking drugs and antagonists
Heerdt PM, Sunaga H, Savarese JJ. Novel neuromuscular blocking drugs and antagonists. Current Opinion In Anaesthesiology 2015, 28: 403-410. PMID: 26087274, DOI: 10.1097/aco.0000000000000209.Peer-Reviewed Original ResearchConceptsMuscle relaxantsClinical trialsNeuromuscular blocking drugsNondepolarizing muscle relaxantsNew muscle relaxantsL-cysteine injectionNondepolarizing drugSugammadex reversalBlocking drugsHistamine releasePreclinical studiesComplete paralysisCysteine injectionClinical developmentCW002RelaxantsRapid reversalIntermediate durationDrugsGantacuriumTrialsInjectionDurationRocuroniumSugammadex